Cardiff Oncology (CRDF) EBIT Margin (2011 - 2026)
Cardiff Oncology (CRDF) posted EBIT Margin of 3220.99% for Q4 2025, up 67.72% sequentially from 9978.33% in Q3 2025, and up 510484.0% YoY from N/an in Q4 2024.
Cardiff Oncology (CRDF) EBIT Margin (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported EBIT Margin for 15 years, with the latest figure at 3220.99% in Q4 2025.
- Quarterly EBIT Margin rose 510484.0% year-over-year to 3220.99% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 8256.32% (down 114360.0% YoY) and the FY2025 annual result came in at 8256.32%, down 113319.0% from the prior year.
- EBIT Margin advanced to 3220.99% in Q4 2025 per CRDF's latest filing, from 9978.33% in the prior quarter.
- Over five years, EBIT Margin peaked at 3220.99% in Q4 2025 and troughed at 14964.86% in Q1 2022.
- A 5-year average of 9207.82% and a median of 8231.52% in 2021 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin surged 918731 bps in 2024, then slumped 786132 bps in 2025.
- Over 5 years, EBIT Margin stood at 7162.41% in 2021, then dropped by 2 bps to 7337.5% in 2022, then climbed by 10 bps to 6623.08% in 2023, then retreated by 26 bps to 8325.83% in 2024, then soared by 61 bps to 3220.99% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 3220.99%, 9978.33%, and 12212.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | -9,245.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9,245.19% |
| Dec 31, 2025 | -3,220.99% |
| Sep 30, 2025 | -9,978.33% |
| Jun 30, 2025 | -12,212.40% |
| Mar 31, 2025 | -13,194.50% |
| Dec 31, 2024 | -8,325.83% |
| Sep 30, 2024 | -7,636.97% |
| Jun 30, 2024 | -7,696.32% |
| Mar 31, 2024 | -5,333.17% |
| Dec 31, 2023 | -6,623.08% |
| Sep 30, 2023 | -7,673.76% |
| Jun 30, 2023 | -11,303.70% |
| Mar 31, 2023 | -14,520.48% |
| Dec 31, 2022 | -7,337.50% |
| Sep 30, 2022 | -9,669.89% |
| Jun 30, 2022 | -11,475.82% |
| Mar 31, 2022 | -14,964.86% |
| Dec 31, 2021 | -7,162.41% |
| Sep 30, 2021 | -8,137.21% |
| Jun 30, 2021 | -10,130.88% |